Newly listed or thinly covered: fundamentals appear here once there is enough reported history. Prices and market cap are up to date.
Share price
₹506.1 latest close · −18.2% over the last 90 sessions
How rough has the ride been?
Drawdown from peak
Largest drawdowns
-27.6% (2026-07 peak to 2026-10 low, not yet recovered)
Most recent volume spikes
2026-11-02: 5.8x the 50-day median, price -7.9% that day
2026-09-30: 5x the 50-day median, price +5.3% that day
2026-08-26: 5.6x the 50-day median, price +0.6% that day
Where does it rank among Health Technology peers?
Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).
Where it ranks today
- ROCE21st
- Op. margin38th
- Debt/equity ↓7th
- Cash cycle ↓35th
- P/E ↓5th
Rank history
Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.
The Health Technology sector page Watch it move against Health Technology in the Observatory
What is the price implying?
At a P/E of 229.7x, the price would imply about 47.1%/yr earnings growth for 10 years under the same assumptions, but it is not ranked.
Fewer than six years of annual earnings are available, which is too little to measure delivered growth.
“Implied growth” is what the current price would require under our stated assumptions, not what we expect.
What prices imply across Health Technology The market-wide Expectations lists
Key figures
- Share Priceclose 9 Nov
- ₹506.10
- P/E
- 145.0x
- ROCE
- 5.0%
- Market Cap
- ₹2236 cr
- Revenue (TTM)
- ₹506 cr
- P/S
- 4.4x
- P/B
- 4.6x
- ROE
- 3.1%
- Operating Margin
- 13.2%
- Debt / Equity
- 1.0x
- Promoter Holding
- 51.2%
Balance sheet & cash
Are profits backed by cash?
Other income reliance87%Beyond threshold
Other income as a share of pre-tax profit (trailing twelve months): 86.9%. Bands: below 15%, 15% to 35%, above 35%.
Tax rate—Not enough data
Not enough reported data to compute this.
Cash conversion2.67xWithin range
Operating cash flow divided by net profit over the last three fiscal years: 2.67x (cash from operations ₹96 cr, net profit ₹36 cr). Bands: 0.8x and above, 0.5x to 0.8x, below 0.5x.
Free cash flow1 of 4 yrsBeyond threshold
Fiscal years with positive free cash flow in the last 4: 1. Bands: at least 80% of years, 40% to 80%, below 40%.
Receivable days vs history—Not enough data
Not enough reported data to compute this.
Capital work in progress58% of fixed assetsWithin range
Capital work-in-progress is 58% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.
Payable days—Not enough data
Not enough reported data to compute this.
Tap a check to see how it is measured
How to read this
Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.
What changed?
7 events since Jun '26
- NovPriceVolume reached 5.8x its 50-day median on 2026-11-02; price -7.9% that day.
- OctPriceFell 28% from the Jul 2026 peak to the Oct 2026 low.
- SepInstitutionsFII + DII holding fell 6.0 pts over 1 quarter to 12.6%.
- JulPriceVolume reached 17.3x its 50-day median on 2026-07-02; price +1.9% that day.
- JunPeer rankSlipped to the bottom quartile of Health Technology on ROCE (from the 2nd quartile).
- JunDebtDebt / equity fell below 1.0x (0.96x).
- JunPriceVolume reached 10.3x its 50-day median on 2026-06-01; price +5.4% that day.
Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.
Where price and fundamentals disagree, market-wide Rewind the whole market to any month
Monthly history8 months · 2026-04 to 2026-11
| Month | P/E | Revenue (TTM) | ROE | ROCE | Debt / Equity |
|---|---|---|---|---|---|
| 2026-11 | 145.0x | ₹506 cr | 3.1% | 5.0% | 1.0x |
| 2026-10 | 149.6x | ₹506 cr | 3.2% | 5.0% | 1.0x |
| 2026-09 | 151.7x | ₹506 cr | 3.2% | 5.0% | 1.0x |
| 2026-08 | 161.1x | ₹381 cr | 2.9% | 5.0% | 1.0x |
| 2026-07 | 169.5x | ₹381 cr | 2.9% | 5.0% | 1.0x |
| 2026-06 | 182.2x | ₹381 cr | 2.9% | 5.0% | 1.0x |
| 2026-05 | 89.5x | ₹163 cr | 15.1% | 17.0% | 1.0x |
| 2026-04 | 89.5x | ₹163 cr | 15.1% | 17.0% | 1.0x |